With consumer confidence hitting its lowest level since January due to inflation concerns and labor market uncertainty, five defensive stocks from consumer staples, healthcare, and utilities sectors are recommended: COCO, DAR, CNC, EXC, and AMRX. These stocks offer upside potential with strong earnings growth estimates and improved analyst consensus over the past 60 days.

Amneal Pharmaceuticals received FDA approval for additional strengths and vial presentations of iohexol injection (350 mg iodine/mL and 300 mg iodine/mL), with planned Q3 2026 launch. The expanded portfolio is expected to address the majority of U.S. iohexol injection market demand, which generated approximately $706 million in annual sales as of May 2026.

DelveInsight's report analyzes the IgE receptor antagonists pipeline with 12+ companies developing therapies for allergic diseases. ADL-018 by Amneal/Kashiv leads in registration stage, while LP-003 by LongBio shows superior Phase II efficacy compared to omalizumab. The market is becoming increasingly competitive with focus on clinical differentiation and speed to market, particularly in China.

Amneal Pharmaceuticals (AMRX) shares rose 3.76% in premarket trading after announcing a definitive agreement to acquire Kashiv BioSciences for $1.1 billion. The acquisition aims to establish Amneal as a fully integrated global biosimilar platform, positioning it to capitalize on a projected $300 billion global biologics loss-of-exclusivity opportunity. The transaction is expected to close in the second half of 2026, subject to shareholder and regulatory approvals.

Amneal Pharmaceuticals announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol on April 14, 2026. These are the company's first two metered-dose inhalation (MDI) product launches, marking entry into the complex inhalation category. The products target large markets worth approximately $1.5 billion and $321 million respectively, manufactured at Amneal's dedicated inhalation facility in Ireland.

The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.

S&P Dow Jones Indices announced index changes effective January 30 and February 2, 2026. TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT will be promoted to the S&P MidCap 400, while Amneal Pharmaceuticals, Apellis Pharmaceuticals, and LegalZoom.com will join the S&P SmallCap 600. These changes follow several pending M&A transactions and corporate actions.

Amneal Pharmaceuticals reported promising interim results from its ELEVATE-PD study for CREXONT, a new extended-release Parkinson's disease treatment. The study showed significant improvements in patient 'Good On' time, reduced 'Off' time, and enhanced motor symptom control across 55 patients.

Amneal Pharmaceuticals executives Chirag Patel and Tasos Konidaris will participate in two upcoming healthcare investor conferences in December 2025 and January 2026, presenting the company's strategic outlook.

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.

Amneal Pharmaceuticals submitted a Biologics License Application (BLA) to the FDA for a biosimilar to XOLAIR, developed with Kashiv BioSciences. The potential entry targets the $4+ billion U.S. market for omalizumab, with expected milestone charges and future growth opportunities.